Acutaas Chemicals Ltd Gains 6.41%: 6 Key Factors Driving the Surge

1 hour ago
share
Share Via
Acutaas Chemicals Ltd delivered a strong weekly performance, rising 6.41% from Rs.2,948.55 to Rs.3,137.60 between 25 and 29 May 2026, significantly outperforming the Sensex which was nearly flat with a 0.01% gain. The stock hit multiple new 52-week and all-time highs during the week, reflecting robust financial results, strong technical momentum, and growing institutional confidence amid mixed broader market conditions.

Key Events This Week

25 May: Stock opens at Rs.2,920.00, down 0.97% despite Sensex rally

26 May: Acutaas Chemicals hits new 52-week and all-time high at Rs.3,038.65

27 May: New 52-week high of Rs.3,070.80 reached, slight daily dip

29 May: Week closes at Rs.3,137.60, marking a 6.41% weekly gain

Week Open
Rs.2,948.55
Week Close
Rs.3,137.60
+6.41%
Week High
Rs.3,074.20
vs Sensex
+0.01%

25 May 2026: Opening Weakness Amid Market Rally

Acutaas Chemicals Ltd started the week at Rs.2,920.00, down 0.97% from the previous close, despite the Sensex gaining 1.23% to close at 35,849.10. The stock’s decline contrasted with the broader market’s positive momentum, reflecting some profit-taking or consolidation after recent gains. Volume was relatively strong at 39,310 shares, indicating active trading interest despite the price dip.

26 May 2026: New 52-Week and All-Time Highs Signal Strong Momentum

The stock rebounded sharply on 26 May, surging 3.84% to close at Rs.3,032.15 and hitting an intraday high of Rs.3,038.65, marking both a new 52-week and all-time high. This represented a significant turnaround from the previous day’s weakness and outperformed the Sensex, which declined marginally by 0.17%. The rally was supported by strong technical indicators, with the stock trading above all key moving averages and signalling renewed buying interest. Institutional investors’ confidence was evident as holdings increased by 0.72% over the previous quarter, underpinning the price strength.

Financially, Acutaas Chemicals continues to impress with net sales growing at an annualised rate of 26.68% and operating profit expanding by 47.03%. The company reported a profit before tax excluding other income of Rs.172.69 crores for the quarter ending March 2026, nearly doubling the previous four-quarter average. These robust fundamentals provide a solid foundation for the stock’s upward trajectory.

Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!

  • - Reliable Performer certified
  • - Consistent execution proven
  • - Large Cap safety pick

Get Safe Returns →

27 May 2026: New Highs Amid Slight Profit Booking

On 27 May, Acutaas Chemicals Ltd reached a fresh 52-week high of Rs.3,070.80, setting another all-time peak. However, the stock closed slightly lower at Rs.3,002.00, down 0.99% on the day, while the Sensex gained 0.31%. This minor pullback after consecutive gains is typical in strong uptrends and did not diminish the overall bullish momentum. The stock remained well above all major moving averages, supported by positive weekly and monthly technical indicators such as MACD and KST.

The company’s financial metrics continued to impress, with a return on capital employed (ROCE) of 28.77% and an inventory turnover ratio of 5.79 times, reflecting operational efficiency. Institutional investors maintained a strong 39.1% stake, further signalling confidence in the company’s prospects.

29 May 2026: Week Closes on a High with New 52-Week Peak

Acutaas Chemicals Ltd closed the week at Rs.3,137.60, up 4.52% on the day and marking a 6.41% gain for the week. The stock hit a new 52-week and all-time high intraday price of Rs.3,074.20, outperforming the Sensex which declined 1.34% to 35,417.64. This strong finish was accompanied by a surge in volume to 45,473 shares, indicating robust investor interest and accumulation.

Technical indicators remained bullish, with the stock trading above all key moving averages and supported by positive MACD, Bollinger Bands, and KST oscillator signals. Despite a bearish monthly RSI, the overall technical outlook suggests sustained upward momentum. The company’s premium valuation metrics, including a price-to-book value of 14.9 and a PEG ratio of 0.6, reflect market recognition of its growth and quality.

Curious about Acutaas Chemicals Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!

  • - Detailed research coverage
  • - Technical + fundamental view
  • - Decision-ready insights

Get the Complete Analysis →

Date Stock Price Day Change Sensex Day Change
2026-05-25 Rs.2,920.00 -0.97% 35,849.10 +1.23%
2026-05-26 Rs.3,032.15 +3.84% 35,787.99 -0.17%
2026-05-27 Rs.3,002.00 -0.99% 35,899.16 +0.31%
2026-05-29 Rs.3,137.60 +4.52% 35,417.64 -1.34%

Key Takeaways

Acutaas Chemicals Ltd demonstrated a strong weekly performance, gaining 6.41% and significantly outperforming the Sensex’s flat movement. The stock’s ability to hit multiple new 52-week and all-time highs reflects robust investor confidence and sustained buying interest.

Financially, the company’s consistent growth in net sales, operating profit, and net profit, alongside a conservative capital structure with a debt-to-equity ratio of 0.05, underpin the stock’s rally. Institutional investors’ increased holdings further validate the company’s fundamentals.

Technically, the stock remains in a bullish phase, trading above all key moving averages with positive momentum indicators such as MACD and KST. However, the elevated valuation metrics, including a price-to-book value near 15 and a PEG ratio around 0.6, suggest the stock is priced for continued strong performance, warranting close monitoring.

Conclusion

The week ending 29 May 2026 was marked by Acutaas Chemicals Ltd’s impressive price appreciation and technical strength, supported by solid financial results and institutional backing. The stock’s outperformance relative to the Sensex and sector peers highlights its leadership position in the Pharmaceuticals & Biotechnology space. While the premium valuation reflects market optimism, the company’s consistent earnings growth and operational efficiency provide a strong foundation for its current momentum. Investors should continue to observe the stock’s technical signals and fundamental updates to gauge the sustainability of this rally.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)